Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 1/2018

01-01-2018 | Retinal Disorders

Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema

Authors: Seung-Young Yu, Dong Heun Nam, Dae Yeong Lee

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2018

Login to get access

Abstract

Purpose

The purpose of this study was to compare the changes in the aqueous cytokine levels after intravitreal bevacizumab with those after combined intravitreal bevacizumab and subtenon triamcinolone injection in diabetic macular edema (DME).

Methods

This study examined 24 eyes of 23 patients with DME. Each patient with DME received randomly either an intravitreal injection of bevacizumab (IVBe) or IVBe with a subtenon triamcinolone injection (IVBe + STTA). Best corrected visual acuity and foveal thickness were evaluated and aqueous samples were obtained before and 4 weeks after the injection. The aqueous concentrations of interleukin (IL)-6, IL-8, interferon-induced protein (IP)-10, monocyte chemotactic protein (MCP)-1, platelet-derived growth factor (PDGF)-AA, and vascular endothelial growth factor (VEGF) were measured using a multiplex bead assay.

Results

After the injection, the foveal thickness decreased more in the IVBe + STTA group than in the IVBe group (P = 0.042). The MCP-1, PDGF-AA, and VEGF levels decreased significantly in the IVBe + STTA group (p = 0.013, p = 0.004 and p = 0.018 respectively), but only the VEGF level decreased in the IVBe group (p = 0.001). IL-8 was significantly increased in the IVBe + STTA group (p = 0.003) but the changes in the VEGF levels were smaller than in the IVBe group (p = 0.025).

Conclusion

Intravitreal bevacizumab and subtenon triamcinolone injection reduces the VEGF, MCP-1 and PDGF-AA levels and increases the IL-8 level in the plural cytokine profiles of patients with DME, which might explain the limited therapeutic effect of combination therapy.
Literature
1.
Funatsu H, Noma H, Mimura T, Eguchi S, Hori S (2009) Association of vitreous inflammatory factors with diabetic macularedema. Ophthalmology 116:73–79CrossRefPubMed
2.
Roh MI, Kim HS, Song JH et al (2009) Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 116:80–86CrossRefPubMed
3.
Sohn HJ, Han DH, Kim IT et al (2011) Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 152:686–694CrossRefPubMed
4.
Meleth AD, Agron E, Chan CC et al (2005) Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 46:4295–4301CrossRefPubMed
5.
Adamis AP, Berman AJ (2008) Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 30:65–84CrossRefPubMed
6.
Marey HM, Ellakwa AF (2011) Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Ophthalmol 5:1011–1016CrossRefPubMedPubMedCentral
7.
Ahmadieh H, Ramezani A, Shoeibi N et al (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246:483–489CrossRefPubMed
8.
Jonas JB, Kreissig I, Sofker A, Degenring RF (2003) Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57–61CrossRefPubMed
9.
Sutter FK, Simpson JM, Gillies MC (2004) Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111:2044–2049CrossRefPubMed
10.
Bakri SJ, Kaiser PK (2005) Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 139:290–294CrossRefPubMed
11.
Diabetic Retinopathy Clinical Research Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115:1447–1459CrossRefPubMedCentral
12.
Ozdek S, Bahceci UA, Gurelik G, Hasanreisoglu B (2006) Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema. J Diabetes Complicat 20:246–251CrossRefPubMed
13.
Shen L, You Y, Sun S et al (2010) Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Ophthalmology 117:2365–2371CrossRefPubMed
14.
Kim MW, Moon H, Yang SJ, Joe SG (2016) Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection. Korean J Ophthalmol 30:25–31CrossRefPubMedPubMedCentral
15.
Shimura M, Yasuda K, Minezaki T, Noma H (2016) Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema. Jpn J Ophthalmol 60:401–407CrossRefPubMed
16.
Adamis AP, Miller JW, Bernal MT et al (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450CrossRefPubMed
17.
Funatsu H, Yamashita H, Nakamura S et al (2006) Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113:294–301CrossRefPubMed
18.
Jin E, Luo L, Bai Y, Zhao M (2015) Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema. Ann Pharmacother 49:387–397CrossRefPubMed
19.
Funatsu H, Yamashita H, Ikeda T et al (2003) Vitreou levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110:1690–1696CrossRefPubMed
20.
Oh IK, Kim SW, Oh J et al (2010) Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res 35:1116–1127CrossRefPubMed
21.
Suzuki Y, Nakazawa M, Suzuki K et al (2011) Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 55:256–263CrossRefPubMed
22.
Lee YS, Choi I, Ning Y et al (2012) Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 106:1833–1841CrossRefPubMedPubMedCentral
23.
Deng Z, Zhou J, Han X, Li X (2016) TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer. Oncol Rep 35:359–365CrossRefPubMed
24.
Jeon S, Lee WK (2014) Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab. Retina 34:1606–1611CrossRefPubMed
25.
Ide N, Hirase T, Nishimoto-Hazuku A et al (2008) Angiotensin II increases expression of IP-10 and the renin-angiotensin system in endothelial cells. Hypertens Res 31:1257–1267CrossRefPubMed
26.
Praidou A, Klangas I, Papakonstantinou E et al (2009) Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res 34:152–161CrossRefPubMed
27.
Hong KH, Ryu J, Han KH (2005) Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105:1405–1407CrossRefPubMed
28.
Hernández C, Segura RM, Fonollosa A et al (2005) Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 22:719–722CrossRefPubMed
29.
Lee WJ, Kang MH, Seong M, Cho HY (2012) Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol 96:1426–1430CrossRefPubMed
30.
Fekete N, Gadelorge M, Fürst D et al (2012) Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: Production process, content and identification of active components. Cytotherapy 14:540–554CrossRefPubMedPubMedCentral
31.
Praidou A, Papakonstantinou E, Androudi S et al (2011) Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema. Acta Ophthalmol 89:248–254CrossRefPubMed
32.
Noma H, Funatsu H, Yamasaki M et al (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 22:42–48CrossRefPubMed
33.
Krohne TU, Eter N, Holz FG, Meyer CH (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508–512CrossRefPubMed
Metadata
Title
Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema
Authors
Seung-Young Yu
Dong Heun Nam
Dae Yeong Lee
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3819-2

Other articles of this Issue 1/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 1/2018 Go to the issue

Basic Science

Repeatability assessment of anterior segment biometric measurements under accommodative and nonaccommodative conditions using an anterior segment OCT

Letter to the Editor

Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy

Review Article

Laser photocoagulation as treatment of non-exudative age-related macular degeneration: state-of-the-art and future perspectives

Glaucoma

Prospective evaluation of CO2 laser-assisted sclerectomy surgery (CLASS) with Mitomycin C

Inflammatory Disorders

Checkpoint inhibitor-induced uveitis: a case series

Glaucoma

Influence of LASEK on Schiøtz, Goldmann and dynamic contour Tonometry